Opioid Overdose

Meet the patient

A 28-year-old man is found unconscious in a park, breathing six times a minute with pinpoint pupils and needle-track marks on one arm. A bystander thinks he injected something about an hour ago.^[1][2]

Two exam questions are now live: what do you do in the first 60 seconds, and when is it safe to let him go? The order is unforgiving — support ventilation before you reverse, and remember that naloxone wears off long before many opioids do. The patient who sits up, declares himself cured and leaves is the one who re-narcotises.^[7][8]

What opioid overdose is — and why the pupils alone never decide

Opioid overdose is the toxic state produced by an excessive dose of any opioid agonist — prescription agents such as morphine, oxycodone, hydrocodone, fentanyl, methadone, tramadol, codeine, and pethidine (meperidine), and the illicit opioid heroin (diacetylmorphine). The defining clinical picture is the classic triad of analytically confirmed opioid toxicity: decreased consciousness, respiratory depression, and miosis. It is one of the great preventable killers of working-age adults — in the United States, opioid overdose is the leading cause of death for Americans 25 to 64 years of age.^[11][7]

The clinical task is to recognise the picture within seconds, support ventilation, and give naloxone promptly — currently the only available treatment for reversing the negative effects of opioids, including respiratory depression. Two truths frame everything that follows. First, opioid overdose is a clinical diagnosis: typical features plus a response to naloxone carry it, and there is no role for waiting on a drug screen. Second, the single trap that kills patients is re-narcotisation — naloxone's duration of effect is shorter than that of many opioid agonists, so a patient who initially recovers can re-sedate and stop breathing again.^[2][8]

The agents — full agonist, partial, mixed, and the killer synthetics

Opioids are classified along three axes that each carry overdose-management implications: receptor behaviour (efficacy), origin, and potency / duration of action. These axes decide how aggressively respiratory depression develops and how demanding naloxone reversal will be. ^[1]

Enlarge

By origin: natural alkaloids (morphine, codeine — from the opium poppy Papaver somniferum); semi-synthetic (heroin, oxycodone, hydrocodone, buprenorphine — chemically modified from natural alkaloids); and fully synthetic (fentanyl, methadone, tramadol, pethidine, propoxyphene — synthesised de novo). The synthetic agents, particularly fentanyl and its analogues, now dominate overdose mortality in North America.^[3]

Who dies — tolerance lost, polysubstance, no bystander

Opioid overdose is a global public health emergency and among the leading causes of accidental death in adults of working age. Synthetic opioids — chiefly fentanyl and its analogues — are the dominant driver of opioid-related death in North America: deaths from synthetic opioids have risen exponentially, and fentanyl is responsible for a large and growing number of overdose deaths, frequently as an adulterant of other drugs without the user's knowledge.^[7][3][14]

Beyond North America the picture differs from country to country — prevention tools such as take-home naloxone are widespread in some countries but minimally available or absent elsewhere, and the World Health Organization issued guidelines on the community management of opioid overdose in 2014.^[20]

^{[16] [15]}

Co-prescribing multiplies the risk: adults exposed to opioids plus benzodiazepines were 20 percent more likely to have an opioid-related overdose than opioid-only users, and those also exposed to non-benzodiazepine sedative-hypnotics were 60 percent more likely. The same cohort study flagged higher opioid dosage strengths, age 65 or over, previous overdose, and substance use disorder as significant risk factors — so avoid the combinations, use the lowest dose possible, and take particular care in exactly these patients.^[15]

Why they stop breathing — the mu receptor and the pre-Bötzinger complex

Opioids act principally at the mu-opioid receptor (MOR, MOP), a Gi/o-coupled seven-transmembrane G-protein-coupled receptor densely distributed in the brain, spinal cord, and periphery. The kappa (KOR) and delta (DOR) receptors contribute less to the classic overdose picture. The classic opioid picture — analgesia, euphoria, sedation, miosis, respiratory depression, and constipation — is overwhelmingly a mu-receptor phenomenon, which is why the opioid-receptor antagonist naloxone reverses it.^[3][10]

The molecular cascade at MOR is: ^[3]

1. Opioid binds MOR → activates inhibitory Gi/o protein.
2. Gi/o inhibits adenylate cyclase → intracellular cyclic AMP (cAMP) falls.
3. GIRK (Kir3) potassium channels open → membrane hyperpolarisation.
4. N-type (and P/Q-type) voltage-gated calcium channels close → reduced neurotransmitter release. ^[3]

The net effect is neuronal inhibition at the sites where MOR is expressed, and the clinical syndrome follows from which centres are inhibited: ^[3]

• Analgesia — inhibition of the descending pain pathway (periaqueductal grey, nucleus raphe magnus, dorsal-horn substantia gelatinosa).
• Euphoria and reward — disinhibition of the ventral tegmental area (VTA) dopamine neurons, the basis of addiction.
• Miosis (pinpoint pupils) — activation of MOR in the Edinger-Westphal nucleus (parasympathetic oculomotor nucleus), increasing parasympathetic tone to the pupillary sphincter.
• Sedation and coma — inhibition of cortical and thalamic arousal circuits and the reticular activating system.
• Respiratory depression (the lethal effect) — direct inhibition of the medullary respiratory centre, especially the pre-Bötzinger complex and the ventral respiratory group. Opioids reduce both the respiratory rate and the ventilatory response to carbon dioxide. Death occurs when bradypnoea progresses to apnoea and then hypoxic cardiac arrest.
• Cough suppression — inhibition of the medullary cough centre.
• Gastrointestinal — increased sphincter tone, reduced peristalsis → constipation and reduced bowel sounds.
• Histamine release — especially morphine → urticaria, pruritus, vasodilation (contributes to hypotension). ^[3]

Enlarge

Naloxone is an opioid-receptor antagonist with no opioid effect of its own. Measured in vivo in the human brain, it displaces opioid tracer from receptor sites in a dose-dependent way — roughly half of receptors occupied at about 1 mg in an adult, consistent with the clinical doses of 0.4 to 1.2 mg used to reverse opiate overdose. Because receptor occupancy is dose-dependent, reversal can be titrated; but a large dose given to an opioid-tolerant patient strips the agonist off receptors abruptly and can precipitate acute opioid-withdrawal syndrome.^[10][8]

Re-narcotisation follows directly from pharmacokinetics: the duration of effect of naloxone is shorter than that of many opioid agonists, and patients who have taken large doses or long-acting formulations risk inadequate response or re-narcotisation even after a successful single dose. Once naloxone clears, residual opioid re-occupies MOR and respiratory depression recurs — sometimes catastrophically, in a patient who appeared fully recovered. This is the single most important concept in opioid-overdose management.^[8]

Fentanyl's anomalous pharmacology deserves specific mention. Fentanyl is 100-fold more potent than morphine and highly lipophilic, crossing quickly between plasma and central nervous target sites — which explains the rapid onset of toxicity after injection. Proposed contributors to its lethality include rapid onset of action, in vivo potency, ligand bias, induction of muscle rigidity and reduced sensitivity to reversal by naloxone; the treatment window after fentanyl-analogue overdose is notably narrow.^[13][3][1]

The classic triad — coma, respiratory depression, pinpoint pupils

The presentation that closes the diagnosis is the triad seen in analytically confirmed opioid (including designer-fentanyl) intoxications: ^[11]

1. Depressed level of consciousness — drowsiness progressing to stupor and coma; in the STRIDA designer-fentanyl series, five of eleven patients required intensive care.
2. Respiratory depression — slow, shallow breathing; may progress to apnoea and respiratory arrest. Respiratory depression is the pivotal vital sign — it is the effect that kills, and the effect naloxone exists to reverse.^[2]
3. Pinpoint pupils (miosis) — via the Edinger-Westphal mechanism above.^[11]

Accompanying signs described across the overdose literature: bradycardia, hypotension, hypothermia, hyporeflexia, reduced or absent bowel sounds, snoring or upper-airway obstruction (from soft-tissue collapse), and — in IV users — needle-track marks or a fresh injection site. Pruritus and urticaria (histamine) occur especially with morphine. Urinary retention from increased bladder-sphincter tone is common.^[1]

Atypical presentations — examiners test these deliberately

• Confirmed designer-fentanyl intoxications still show the classic triad — decreased consciousness, respiratory depression, and miosis — yet one of eleven patients died of brain oedema: a classic-looking picture does not mean a benign course.^[11]
• Polydrug use is the rule, not the exception — additional psychoactive substances (e.g. benzodiazepine-type novel drugs) were detected in about half of confirmed designer-fentanyl cases, deepening coma and complicating reversal.^[11][1]
• Tramadol / propoxyphene — seizures and respiratory depression are dose-related in tramadol overdose; serotonin toxicity appears unlikely (no Hunter-criteria cases in the largest series).^[17]
• Methadone — QTc prolongation with risk of torsades de pointes and sudden cardiac death through hERG inhibition; may present with syncope or cardiac arrest rather than the classic triad.^[5]
• Buprenorphine — partial agonist; the adult ceiling on respiratory depression may not protect children.^[18]
• Delayed or prolonged toxicity with long-acting agents — long-acting opioids are particularly resistant to naloxone and demand prolonged observation.^[2]
• Non-cardiogenic pulmonary oedema — people who use opioids may develop pulmonary oedema as a complication; support oxygenation rather than expecting naloxone to fix it.^[7]

The mimics — and the bedside tests that end each

A comatose patient with small pupils has a focused but critical differential. All must be considered at the bedside. The cardinal principle stands: check glucose immediately, support ventilation, and give naloxone while you think — and remember that co-ingested non-opioid substances can be contributing, for which naloxone is not an effective treatment.^[1]

When a comatose patient arrives the bedside glucose must be checked immediately (hypoglycaemia is the great mimic and is rapidly fatal if missed), and a paracetamol and salicylate level sent on every intentional overdose — because of co-ingestion of an over-the-counter analgesic that has its own specific antidote (N-acetylcysteine, alkalinisation). ^[1]

The bedside minute — recognise, ventilate, reverse

A rapid, structured assessment at the bedside secures the priorities. The aim is to recognise opioid toxicity within a minute, exclude the mimics in parallel, and reverse while supporting ventilation. ^[7]

• Airway and Breathing — respiratory depression is the pivotal sign; assess depth, cyanosis, use of accessory muscles, and upper-airway obstruction (snoring). Pulse oximetry is useful but lags — do not wait for a low saturation before acting. An arterial or venous blood gas shows respiratory acidosis — the biochemical signature of opioid respiratory depression.
• Circulation — bradycardia and hypotension (often mild); check capillary refill and temperature (hypothermia).
• Disability — level of consciousness, pupil size and reactivity (pinpoint pupils suggest opioid), and bedside glucose (the first test in any comatose patient).
• Exposure — search for a MedicAlert, a fentanyl or buprenorphine patch on the skin (remove it!), needle-track marks, drug paraphernalia, and signs of trauma.
• History — from paramedics, family, or the patient's belongings: which opioid, what dose, what route, what time, any co-ingestants, and whether the patient is on long-term opioid therapy or opioid agonist treatment (which changes the reversal plan). ^[1]

Response to naloxone supports the diagnosis — but a poor response does not exclude an opioid. Reversal effectiveness varies with the opioid's pharmacokinetics and pharmacodynamics: long-acting opioids, and those with high µ-receptor affinity or slow receptor dissociation kinetics, are particularly resistant to naloxone. And when other non-opioid substances are contributing to the overdose, naloxone is not an effective treatment for them.^[2][1]

Look actively for complications: aspiration pneumonitis (rales, wheeze, reduced air entry, fever if delayed), non-cardiogenic pulmonary oedema (bilateral crackles, frothy sputum, hypoxia), and rhabdomyolysis (firm, swollen, tender muscle groups, dark urine, rising creatine kinase) from prolonged immobilisation on a hard surface. ^[7][1]

Physiology, not numbers — the investigations that change the plan

Opioid overdose is a clinical diagnosis — no laboratory result is required to start treatment. Investigations are used to confirm the bedside picture, exclude mimics and co-ingestants, and detect complications.^[1]

• Capillary glucose (bedside) — the first test in any comatose patient; hypoglycaemia is the great mimic and needs immediate treatment with IV dextrose.
• Arterial or venous blood gas — respiratory acidosis (low pH, high PaCO2) confirms significant respiratory depression; repeat after naloxone to confirm reversal.
• ECG — mandatory in opioid overdose. QTc prolongation is the signature of methadone (risk of torsades de pointes and sudden cardiac death via hERG inhibition); also check for the QRS widening of tricyclic co-ingestion and the dysrhythmias of hypoxia.^[5]
• Paracetamol and salicylate levels — sent on every intentional overdose, because co-ingestion of an over-the-counter analgesic is common and has a time-critical specific antidote.
• Serum and urine drug screen — qualitative; useful for detecting co-ingestants, but standard immunoassays do not reliably detect fentanyl, and detecting novel fentanyls requires specific LC-MS methods not commonly available in hospitals.^[11]
• CK, urea, creatinine, electrolytes — to detect rhabdomyolysis and acute kidney injury from prolonged immobilisation.
• Chest X-ray — to detect aspiration, pulmonary oedema, and to check tube placement if intubated.
• CT brain — if the patient fails to respond to adequate naloxone, or if focal neurological signs are present.

There is no single 'opioid level' of clinical use in the acute setting — opioid serum concentrations do not correlate tidily with clinical severity, and turnaround time is too long. Treatment is guided by physiology, not numbers. ^[1]

Ventilate first, reverse second — why the order saves lives

Enlarge

^{[7] [8] [2]}

The resuscitation bundle is time-critical and must be delivered in parallel, in the following order of priority:^[7]

1. Airway — protect and open. Clear the airway; consider a nasopharyngeal or oropharyngeal airway; position laterally if unprotected. Snoring = upper-airway obstruction from soft-tissue collapse — correct it immediately. Remove any transdermal patch and wipe the skin clean.
2. Breathing — effective ventilation FIRST. Emergency management of opioid poisoning demands effective ventilation coupled to compressions in the arrest setting, and bystander programmes teach rescue breathing alongside naloxone. A few effective breaths restore oxygenation and buy the time naloxone needs to work.^[7][6]
3. Circulation — IV access; isotonic fluids for hypotension; cardiac monitoring (especially for methadone QT).
4. Disability — bedside glucose, then naloxone. Check glucose immediately and treat hypoglycaemia; then administer naloxone, repeated as needed to restore adequate respiration.^[1]
5. Exposure and history — identify the agent, dose, time, route, and co-ingestants. ^[1]

Why ventilation first? The pathophysiology of opioid-associated arrest is asphyxial: prolonged hypoxaemia leading to global ischaemia, which differs from sudden cardiac arrest — so effective ventilation is the core of resuscitation, with naloxone administered to prevent cardiac arrest in the first place.^[7]

Endotracheal intubation versus naloxone — naloxone can make intubation unnecessary, but when reversal remains inadequate — naloxone-resistant long-acting or high-affinity opioids, or non-opioid substances contributing to the overdose — airway support and ventilation continue regardless.^[2]

Naloxone to adequate respiration — and the re-narcotisation clock

Naloxone dosing

Naloxone is an opioid-receptor antagonist whose in-vivo receptor occupancy is dose-dependent: about half of opioid receptors occupied at roughly 1 mg in an adult, consistent with clinical reversal doses of 0.4 to 1.2 mg.^[10] Out of hospital, 2 mg intranasal or intramuscular naloxone reversed suspected heroin overdose, with adequate response in about 8 minutes on average for either route.^[9]

^{[10] [9] [12]}

Titration endpoint — adequate respiration, not full alertness. Reversal of opioid toxicity may precipitate an opioid-withdrawal syndrome (agitation, vomiting, diarrhoea, tachycardia, piloerection, lacrimation, rhinorrhoea, muscle cramps), and over-reversal can make an opioid-tolerant patient agitated enough to discharge themselves — only to re-narcotise after naloxone wears off.^[8]

Repeat dosing: if the initial dose works but the patient re-sedates, give more naloxone. After large ingestions or long-acting formulations a single dose risks inadequate response or re-narcotisation, because naloxone's duration of effect is shorter than that of many opioid agonists. If reversal remains poor, suspect a long-acting or high-affinity opioid — particularly naloxone-resistant — or a contributing non-opioid substance, and keep ventilating.^[8][2][1]

When one dose is not enough

For long-acting opioids and large ingestions, one dose is rarely the end of the story: patients who have taken large doses or long-acting formulations risk inadequate response or re-narcotisation after a single dose of naloxone.^[8] Long-acting opioids, and agents with high µ-receptor affinity or slow receptor dissociation kinetics, are particularly resistant to naloxone — plan repeat boluses or a continuous infusion with prolonged observation rather than a single reversal.^[2] Even when naloxone works — as it did for the designer-fentanyl intoxications in the Swedish STRIDA series — patients still needed acute and intensive hospital care.^[11]

Decontamination

• Activated charcoal — only early after an oral ingestion, and only if the airway is protected (the patient is awake and cooperative or intubated). Of little use in the typical IV heroin overdose.
• Whole-bowel irrigation — for body-packers with intact packets, using polyethylene glycol solution, once the airway is secured.
• Haemodialysis — not effective for opioid removal (large volume of distribution, high protein binding, extensive tissue distribution); manage with supportive care and naloxone. ^[1]

Observation and disposition (re-narcotisation)

Because naloxone's duration of effect is shorter than that of many opioids, every patient must be observed for recurrence of respiratory depression:^[8][12]

• Short-acting opioids (e.g. heroin), good response, no co-intoxicants — an ED observation period of one hour is sufficient: if after that the patient mobilises as usual, has normal vital signs, and a GCS of 15, they can be discharged safely.^[12]
• How real is rebound after refusal of transport? Pooled across the observational literature, among 5443 patients treated with naloxone and not transported, there were four deaths from rebound opioid toxicity — a number needed to transport of 1361 to save one life. Rare, but not zero; counsel and offer take-home naloxone.^[12]
• Long-acting opioids, large ingestions, or co-ingestants — prolonged observation with repeat naloxone or infusion as required, because these are the patients at risk of inadequate response and re-narcotisation.^[8][2]
• Pulmonary oedema, significant co-ingestants, recurrent apnoea, body-packers, or suicide intent — admit. ^[1]

Harm reduction (the discharge bundle)

Before discharge, the American Heart Association and national guidelines converge on: overdose education and take-home naloxone; medication for opioid use disorder (MOUD) — while receiving opioid agonist treatment the all-cause mortality rate is less than half the rate out of treatment; linkage to ongoing methadone or buprenorphine treatment, which hospital guidelines specifically recommend along with ensuring naloxone access at discharge.^[7][19][4]

Scenarios you will actually meet

Fentanyl and ultra-potent synthetic opioids

Fentanyl is 100-fold more potent than morphine and highly lipophilic (octanol:water partition coefficient over 700), crossing quickly between plasma and CNS. Overdose onset is rapid, with a narrow window for treatment; fentanyl shows reduced sensitivity to reversal by naloxone — yet in analytically confirmed designer-fentanyl intoxications, naloxone was effective to reverse the opioid symptoms, and the published argument that naloxone simply does not work against fentanyl analogues rests on limited evidence.^{[13][1][3][11]} Carfentanil is the most dangerous fentanyl derivative — an adulterant of other illicit drugs and counterfeit pharmaceuticals, taken by injection, insufflation, or inhalation — and its extraordinary potency means that reversing its severe and recurring respiratory depression requires multiple or higher than standard doses of naloxone. Carfentanil use is strongly connected to polydrug use, and detection requires specific analytical methods not commonly available in hospitals.^[14]

Body-packers and body-stuffers

• Body-packers swallow carefully packaged drug (usually condoms or pellets) for smuggling; toxicity occurs if a packet ruptures, causing massive, often fatal overdose. Manage with whole-bowel irrigation once the airway is secured; surgery is indicated for bowel obstruction, packet rupture, or failure to pass packets. Serial imaging tracks packet transit.
• Body-stuffers hastily swallow loosely wrapped drug to avoid arrest; they are at higher and more immediate risk of rupture and toxicity. Observe, image, and decontaminate proactively. ^[1]

Tramadol overdose

Tramadol is a weak MOR agonist plus a serotonin and noradrenaline reuptake inhibitor. The largest case series (71 patients) showed seizures and respiratory depression related to the ingested dose: seizures occurred in 8 patients, respiratory depression in 13 (median ingested dose 2500 mg versus 1000 mg in those without), and no cases of serotonin toxicity met the Hunter criteria. CNS depression was common (GCS under 15 in 29 of 71). Treat seizures with benzodiazepines and support respiration.^[17]

Methadone overdose

Methadone inhibits the hERG channel — dose-associated QTc prolongation, torsades de pointes, and sudden cardiac death — so the ECG and continuous cardiac monitoring are part of methadone overdose care.^[5] As a long-acting opioid it is among the agents particularly resistant to naloxone: plan prolonged observation and repeat dosing or infusion rather than a single reversal.^[2]

Mixed / polysubstance overdose

Co-ingestion multiplies risk: every additional illicit drug combined with opioids nearly doubles the risk of death from opioids, and concurrent benzodiazepine exposure in opioid users raises overdose risk by about 20 percent — about 60 percent when non-benzodiazepine sedative-hypnotics are added. Manage with ventilation, naloxone, and supportive care; treat the most dangerous co-ingestant specifically (e.g. N-acetylcysteine for paracetamol, sodium bicarbonate for tricyclic QRS widening, haemodialysis for salicylate). ^[16][15]

Buprenorphine overdose

A partial mu-agonist with high receptor affinity and a ceiling effect on respiratory depression in adults — the reason it is generally regarded as safer than methadone. But the ceiling may not apply to children: a fatal case followed a small child's ingestion of a caretaker's buprenorphine/naloxone combination, with dose-dependent respiratory depression and no other drugs detected. In adults with co-sedatives, support ventilation rather than relying on ever-larger naloxone doses. ^[18]

How the patient comes to harm — the preventable list

Other pitfalls: relying on pulse oximetry (it lags — act on the breathing); assuming opioid because pupils are small (clonidine, pontine stroke, organophosphates); assuming not opioid because the response to naloxone is poor (naloxone-resistant long-acting and high-affinity opioids exist, and non-opioid co-ingestants may be contributing); discharging too early and losing the patient to re-narcotisation; failing to send a paracetamol/salicylate level in every overdose; forgetting to remove a fentanyl patch; and giving high-dose naloxone to an opioid-tolerant patient and precipitating violent withdrawal and self-discharge.^[2][1][8]

Who goes home, who stays — the opioid decides the observation window

Prognostic factors: the time to effective ventilation (the chief determinant of anoxic brain injury), the presence of co-ingestants (which deepen coma and complicate reversal), the development of pulmonary oedema or aspiration, and comorbidity. Most pure opioid overdoses that are ventilated early and reversed promptly do well; death is from hypoxic cardiac arrest when ventilation is delayed.^[7]

Pre-hospital naloxone saves lives: community overdose-education and nasal-naloxone distribution programmes in Massachusetts trained 2912 potential bystanders who reported 327 rescues, and communities with the highest enrolment rates had significantly lower opioid-overdose death rates. Bystander naloxone programmes report survival rates of 96 to 99 percent and higher across studies. The programmes deliberately train opioid users, social service staff, family, and friends in rescue breathing and naloxone use.^[6][12]

Safe discharge (after a short-acting opioid overdose with a good response and no co-intoxicants):

• Observe for one hour; the patient should be mobilising as usual, with normal vital signs and a GCS of 15.^[12]
• Take-home naloxone with overdose-recognition training provided;^[7]
• Follow-up (addiction medicine, mental health) arranged — medication for opioid use disorder halves mortality.^[19]

Admit/observe longer for: long-acting opioids and large ingestions (particularly naloxone-resistant); pulmonary oedema; significant co-ingestants; recurrent apnoea after naloxone; body-packers; suicide intent needing psychiatric admission; and any patient needing repeat dosing or a naloxone infusion. ^[2][8]

Special populations — children, pregnancy, the opioid-tolerant

Children

Most paediatric exposures are accidental ingestion of an adult's medication in the household. Children are not protected by the pharmacology that protects adults: in a fatal case, a small child ingested a caretaker's buprenorphine/naloxone combination, and postmortem toxicology showed only buprenorphine and norbuprenorphine — the theoretical safety of the ceiling effect on respiratory depression may not apply to children, in whom dose-dependent respiratory depression can occur. Store opioids where children cannot reach them.^[18]

Pregnancy

Naloxone crosses the placenta but is safe in pregnancy — maternal resuscitation takes priority, and maternal hypoxia is far more dangerous to the fetus than naloxone. Avoid over-reversal, which can precipitate acute maternal withdrawal. Be alert to fetal bradycardia from maternal respiratory depression and monitor the fetus once the mother is stabilised. After birth, watch for neonatal opioid withdrawal syndrome (NOWS / neonatal abstinence syndrome) if the mother is opioid-dependent; manage with non-pharmacological care (swaddling, low-stimulation environment, frequent small feeds) and, if needed, opioid therapy per a validated score.^[1]

Opioid-tolerant and OAT patients

For patients on chronic opioid therapy, OAT (methadone/buprenorphine), or with opioid use disorder: reversal of opioid toxicity may precipitate acute withdrawal, so titrate naloxone to adequate respiration, not full reversal.^[8] Guidelines recommend continuing or ensuring linkage to methadone or buprenorphine treatment rather than interrupting it, and ensuring naloxone access;^[4] while receiving OAT the all-cause mortality rate is less than half the rate out of treatment, and secondary prevention after an overdose explicitly includes MOUD.^[19][7]

Elderly and frail

Age 65 or over is a significant risk factor for opioid overdose, alongside higher opioid dosage strengths, previous overdose, and substance use disorder. Concurrent benzodiazepine exposure raises overdose risk by about 20 percent, and adding non-benzodiazepine sedative-hypnotics takes it to about 60 percent above opioid-only users — so use the lowest dose possible and particular caution in older adults.^[15]

Evidence and the names that score marks

The American Heart Association scientific statement (2021) reframed opioid overdose around three pillars: prompt recognition and effective ventilation (opioid-associated arrest is asphyxial); naloxone for everyone — emergency personnel, trained laypeople, and the general public; and secondary prevention — counselling, overdose education with take-home naloxone, and medication for opioid use disorder.^[7] The 2022 systematic review of hospital-based guidelines by Calcaterra and colleagues found consensus that hospitalised patients with opioid use disorder should receive methadone or buprenorphine, linkage to ongoing treatment, and naloxone access at discharge.^[4]

Landmark evidence: the Massachusetts interrupted-time-series analysis (Walley and colleagues, BMJ 2013) tied community naloxone distribution to lower overdose death rates;^[6] the Santo and colleagues meta-analysis (JAMA Psychiatry 2021, over 750,000 participants) showed all-cause mortality during opioid agonist treatment is less than half the rate out of treatment;^[19] the Swedish STRIDA project documented the classic triad and naloxone effectiveness in analytically confirmed designer-fentanyl intoxications;^[11] Kelly and colleagues defined fentanyl's 'anomalous' pharmacology — rapid onset, in-vivo potency, reduced naloxone sensitivity — that now shapes the higher-dose naloxone debate;^[3] and the hERG systematic review established that methadone (and fentanyl) inhibit the hERG channel, causing QTc prolongation, torsades de pointes, and sudden cardiac death.^[5]

Controversies: whether standard naloxone doses still suffice in the fentanyl era — the published argument that naloxone is ineffective against fentanyl and its analogues rests on case studies, retrospective outbreak analyses, and pharmacokinetic/pharmacodynamic reasoning with no well-controlled studies, and the current literature provides limited evidence that naloxone is ineffective against fentanyl-analogue overdose; the central concern is instead the rapidity of overdose onset and the narrow window for treatment.^[1] Carfentanil is the exception in degree — multiple or higher than standard doses are required for its recurring respiratory depression.^[14] And as out-of-hospital naloxone use grows, so does the tension of effective but safe dosing, because reversal may precipitate opioid withdrawal.^[8]

The mantra, and the memory devices

The mantra: ventilate first, naloxone to adequate respiration, and outlast the opioid — the breathing decides, not the pupils.^[7][8]

^{[11] [7] [10] [9] [3] [14] [8]}

• The classic triad: decreased consciousness + respiratory depression + miosis. Confirmed analytically in designer-fentanyl intoxications — but polydrug use is common and can muddy the picture.^[11]
• Ventilate first, then naloxone. Opioid arrest is asphyxial; effective ventilation coupled to compressions, with naloxone to prevent the arrest.^[7]
• Naloxone: 0.4 to 1.2 mg IV reversal doses; 2 mg intranasal or IM out of hospital; repeat as needed. Over-reversal precipitates acute withdrawal.^[10][9][8]
• The killer is re-narcotisation. Naloxone's duration is shorter than many opioids; after large doses or long-acting agents a single dose is not the end.^[8]
• Fentanyl is 100-fold morphine; carfentanil needs more naloxone. Rapid onset, narrow window, reduced naloxone sensitivity — yet naloxone reversed confirmed designer-fentanyl cases.^[13][14][11]
• Methadone: hERG → long QT. QTc prolongation, torsades, sudden cardiac death — monitor the ECG.^[5]
• Tramadol: dose-related seizures and respiratory depression; serotonin toxicity appears unlikely.^[17]
• Harm reduction: take-home naloxone + medication for opioid use disorder at discharge.^[7][19]

Ward-round test — three stems, a minute each

Stem 1 — he wakes up and demands to leave (answer)ShowHide

The man from the vignette is ventilated, given intravenous naloxone, and within a few minutes he is alert, orientated and angry, demanding discharge against advice. His oxygen saturation is 99 percent on room air. What is the safe plan? Model: Do not simply wave him out — but compulsory transport is not automatic either. Rebound opioid toxicity after naloxone is rare but real: across pooled observational data, among 5443 patients treated and not transported there were four deaths (number needed to transport 1361). The evidence-based plan: observe for one hour; if he mobilises as usual with normal vital signs and a GCS of 15, and there are no co-intoxicants, discharge is considered safe — but only with overdose education, take-home naloxone for him and those around him, and linkage to medication for opioid use disorder, which more than halves mortality. If he had needed repeated dosing for a long-acting opioid, he would stay.^[12][7][19]

Stem 2 — apnoeic, but the pupils are normal (answer)ShowHide

A 24-year-old is brought in apnoeic and cyanosed after a suspected overdose, but his pupils are midsize and reactive, not pinpoint. Does this exclude an opioid? Model: No. Diagnosis is clinical and the management is unchanged: support ventilation first, then give naloxone — a clear response supports an opioid cause. But neither pupil size nor a poor naloxone response excludes opioid toxicity: reversal effectiveness varies with the opioid's pharmacokinetics and pharmacodynamics, long-acting opioids and high-affinity/slow-dissociation agents are particularly naloxone-resistant, and non-opioid co-ingestants may be contributing, for which naloxone is not effective treatment. In confirmed designer-fentanyl cases even the classic triad coexisted with co-detected benzodiazepine-type drugs in about half the patients. Keep ventilating whatever the pupils say.^{[7][2][1][11]}

Stem 3 — methadone, a long-acting opioid and a long QT (answer)ShowHide

A 45-year-old on methadone maintenance is found deeply sedated with a respiratory rate of 6. The ECG shows a QTc of 520 ms. What is different about his management? Model: Two things. First, methadone inhibits the hERG channel — that long QTc carries a real risk of torsades de pointes and sudden cardiac death, so he needs continuous cardiac monitoring and ECG follow-up. Second, as a long-acting opioid he is in the category particularly resistant to naloxone: expect repeat boluses or a continuous infusion with prolonged observation, not a single reversal — naloxone's duration of effect is shorter than that of many opioid agonists, and re-narcotisation after one dose is exactly the trap. Remove any transdermal patch, check paracetamol and salicylate levels, and arrange addiction-medicine follow-up — and do not stop his methadone; linkage to ongoing agonist treatment is the guideline recommendation and halves mortality.^{[5][2][8][4][19]}

References20ShowHide

1. [1]Britch SC, Walsh SL. Treatment of opioid overdose: current approaches and recent advances Psychopharmacology (Berl), 2022.PMID 35385972
2. [2]van Lemmen M, Florian J, Li Z, et al. Opioid Overdose: Limitations in Naloxone Reversal of Respiratory Depression and Prevention of Cardiac Arrest Anesthesiology, 2023.PMID 37402248
3. [3]Kelly E, Sutcliffe K, Cavallo D, et al. The anomalous pharmacology of fentanyl Br J Pharmacol, 2023.PMID 34030211
4. [4]Calcaterra SL, Bottner R, Martin M, et al. Management of opioid use disorder, opioid withdrawal, and opioid overdose prevention in hospitalized adults: A systematic review of existing guidelines J Hosp Med, 2022.PMID 35880821
5. [5]El Sherbini A, Liblik K, Lee J, et al. Opioids-induced inhibition of HERG ion channels and sudden cardiac death, a systematic review of current literature Trends Cardiovasc Med, 2024.PMID 37015297
6. [6]Walley AY, Xuan Z, Hackman HH, et al. Opioid overdose rates and implementation of overdose education and nasal naloxone distribution in Massachusetts: interrupted time series analysis BMJ, 2013.PMID 23372174
7. [7]Dezfulian C, Orkin AM, Maron BA, et al. Opioid-Associated Out-of-Hospital Cardiac Arrest: Distinctive Clinical Features and Implications for Health Care and Public Responses: A Scientific Statement From the American Heart Association Circulation, 2021.PMID 33682423
8. [8]Rzasa Lynn R, Galinkin JL. Naloxone dosage for opioid reversal: current evidence and clinical implications Ther Adv Drug Saf, 2018.PMID 29318006
9. [9]Kerr D, Kelly AM, Dietze P, et al. Randomized controlled trial comparing the effectiveness and safety of intranasal and intramuscular naloxone for the treatment of suspected heroin overdose Addiction, 2009.PMID 19922572
10. [10]Melichar JK, Nutt DJ, Malizia AL. Naloxone displacement at opioid receptor sites measured in vivo in the human brain Eur J Pharmacol, 2003.PMID 12524149
11. [11]Helander A, Bäckberg M, Signell P, Beck O. Intoxications involving acrylfentanyl and other novel designer fentanyls - results from the Swedish STRIDA project Clin Toxicol (Phila), 2017.PMID 28349714
12. [12]Willman MW, Liss DB, Schwarz ES, Mullins ME. Do heroin overdose patients require observation after receiving naloxone? Clin Toxicol (Phila), 2017.PMID 27849133
13. [13]Lötsch J, Walter C, Parnham MJ, et al. Pharmacokinetics of non-intravenous formulations of fentanyl Clin Pharmacokinet, 2013.PMID 23100195
14. [14]Zawilska JB, Kuczyńska K, Kosmal W, et al. Carfentanil - from an animal anesthetic to a deadly illicit drug Forensic Sci Int, 2021.PMID 33581655
15. [15]Cho J, Spence MM, Niu F, et al. Risk of Overdose with Exposure to Prescription Opioids, Benzodiazepines, and Non-benzodiazepine Sedative-Hypnotics in Adults: a Retrospective Cohort Study J Gen Intern Med, 2020.PMID 31919729
16. [16]Møller LF, Matic S, van den Bergh BJ, et al. Acute drug-related mortality of people recently released from prisons Public Health, 2010.PMID 20888607
17. [17]Ryan NM, Isbister GK. Tramadol overdose causes seizures and respiratory depression but serotonin toxicity appears unlikely Clin Toxicol (Phila), 2015.PMID 25901965
18. [18]Kim HK, Smiddy M, Hoffman RS, Nelson LS. Buprenorphine may not be as safe as you think: a pediatric fatality from unintentional exposure Pediatrics, 2012.PMID 23129079
19. [19]Santo T Jr, Clark B, Hickman M, et al. Association of Opioid Agonist Treatment With All-Cause Mortality and Specific Causes of Death Among People With Opioid Dependence: A Systematic Review and Meta-analysis JAMA Psychiatry, 2021.PMID 34076676
20. [20]McDonald R, Campbell ND, Strang J. Twenty years of take-home naloxone for the prevention of overdose deaths from heroin and other opioids-Conception and maturation Drug Alcohol Depend, 2017.PMID 28654870